Radiographic response and clinical toxicity following SBRT for stage I lung cancer

Jeffrey Bradley

Research output: Contribution to journalArticle

37 Scopus citations


Clinical outcomes following stereotactic body radiation therapy (SBRT) for stage I non-small cell lung cancer (NSCLC) are excellent, with local control rates ranging from 80% to 95% in medically inoperable patients. Toxicity following SBRT has been lower than expected, with exception for grade 3 to 5 events occurring in patients treated with high doses to mediastinal structures. In considering a randomized head-to-head comparison of SBRT versus surgery for stage I lung cancer, the interpretation of clinical response based on imaging is of great importance. This is because of the opportunity to salvage SBRT local failure with surgery in operable patients. The current literature is reviewed with respect to computed tomography (CT) and positron emission tomography (PET) with respect to response following SBRT. The reported toxicities following SBRT for both peripheral and central lung cancers are also reviewed.

Original languageEnglish
Pages (from-to)S118-S124
JournalJournal of Thoracic Oncology
Issue number7 SUPPL.3
StatePublished - Jul 1 2007


  • Computed tomography response
  • Lung cancer
  • Positron emission tomography
  • Pulmonary function
  • Stereotactic body radiation therapy

Fingerprint Dive into the research topics of 'Radiographic response and clinical toxicity following SBRT for stage I lung cancer'. Together they form a unique fingerprint.

  • Cite this